tradingkey.logo
tradingkey.logo
Buscar

Tivic Health Systems Inc

TIVC
Añadir a la lista de seguimiento
1.400USD
0.0000.00%
Horarios del mercado ETCotizaciones retrasadas 15 min
2.92MCap. mercado
PérdidaP/E TTM

Tivic Health Systems Inc

1.400
0.0000.00%

Más Datos de Tivic Health Systems Inc Compañía

Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.

Información de Tivic Health Systems Inc

Símbolo de cotizaciónTIVC
Nombre de la empresaTivic Health Systems Inc
Fecha de salida a bolsaNov 11, 2021
Director ejecutivoErnst (Jennifer)
Número de empleados7
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 11
Dirección47685 Lakeview Blvd
CiudadFREMONT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94538
Teléfono18882766888
Sitio Webhttps://tivichealth.com/
Símbolo de cotizaciónTIVC
Fecha de salida a bolsaNov 11, 2021
Director ejecutivoErnst (Jennifer)

Ejecutivos de Tivic Health Systems Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
32.69K
+28.89%
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
10.00K
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
32.69K
+28.89%
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
10.00K
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: jue., 7 de may
Actualizado: jue., 7 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Avenue Capital Group
3.24%
Geode Capital Management, L.L.C.
2.81%
Sanctuary Advisors, LLC
1.95%
Marex Group plc
1.89%
3I Management LLC
1.50%
Otro
88.62%
Accionistas
Accionistas
Proporción
Avenue Capital Group
3.24%
Geode Capital Management, L.L.C.
2.81%
Sanctuary Advisors, LLC
1.95%
Marex Group plc
1.89%
3I Management LLC
1.50%
Otro
88.62%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
7.54%
Investment Advisor
3.80%
Individual Investor
2.26%
Research Firm
0.16%
Hedge Fund
0.05%
Otro
86.19%

Participación institucional

Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
23
362.58K
11.55%
+205.09K
2025Q4
22
224.75K
8.90%
+144.85K
2025Q3
22
44.96K
2.86%
+5.91K
2025Q2
32
112.57K
10.82%
+62.79K
2025Q1
32
1.24K
0.18%
-48.58K
2024Q4
34
288.82K
2.82%
-516.93K
2024Q3
32
301.13K
4.87%
-468.33K
2024Q2
32
639.36K
10.34%
+419.46K
2024Q1
34
88.08K
6.01%
-141.85K
2023Q4
34
75.33K
5.40%
-149.34K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Avenue Capital Group
101.64K
3.53%
+101.64K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
7.73K
0.27%
--
--
Jan 31, 2026
Marex Group plc
40.94K
1.42%
+2.55K
+6.64%
Dec 31, 2025
3I Management LLC
47.05K
1.64%
+47.05K
--
Feb 21, 2026
Ernst (Jennifer)
32.69K
1.14%
+9.44K
+40.62%
Dec 26, 2025
Susquehanna International Group, LLP
14.64K
0.51%
+14.64K
--
Dec 31, 2025
Handley Michael K
8.82K
0.31%
+8.82K
--
Feb 18, 2026
Ver más

ETFs relacionados

Nombre
Proporción
Sin datos

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
KeyAI